CN113613635A - 使用脂质缀合的核心支架的高密度脂蛋白模拟纳米颗粒 - Google Patents

使用脂质缀合的核心支架的高密度脂蛋白模拟纳米颗粒 Download PDF

Info

Publication number
CN113613635A
CN113613635A CN202080010616.0A CN202080010616A CN113613635A CN 113613635 A CN113613635 A CN 113613635A CN 202080010616 A CN202080010616 A CN 202080010616A CN 113613635 A CN113613635 A CN 113613635A
Authority
CN
China
Prior art keywords
hdl
spherical
dna
core
spherical hdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080010616.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·E·寒里驰
C·S·泰克斯丹
S·T·钮银
洪凤振
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of CN113613635A publication Critical patent/CN113613635A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202080010616.0A 2019-01-24 2020-01-24 使用脂质缀合的核心支架的高密度脂蛋白模拟纳米颗粒 Pending CN113613635A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796534P 2019-01-24 2019-01-24
US62/796,534 2019-01-24
PCT/US2020/015109 WO2020154705A1 (en) 2019-01-24 2020-01-24 High-density lipoprotein mimetic nanoparticles using lipid conjugated core scaffolds

Publications (1)

Publication Number Publication Date
CN113613635A true CN113613635A (zh) 2021-11-05

Family

ID=71736549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010616.0A Pending CN113613635A (zh) 2019-01-24 2020-01-24 使用脂质缀合的核心支架的高密度脂蛋白模拟纳米颗粒

Country Status (9)

Country Link
US (1) US12502354B2 (https=)
EP (1) EP3914236A4 (https=)
JP (1) JP7546927B2 (https=)
CN (1) CN113613635A (https=)
AU (2) AU2020210881A1 (https=)
CA (1) CA3127256A1 (https=)
MX (1) MX2021008940A (https=)
SG (1) SG11202107156WA (https=)
WO (1) WO2020154705A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011207563B2 (en) 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
US20230173096A1 (en) * 2020-05-18 2023-06-08 Northwestern University Targeted antiviral drugs
CA3199462A1 (en) 2020-10-23 2022-04-28 Northwestern University Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles
KR102402620B1 (ko) * 2021-06-01 2022-05-30 임덕수 약물 전달을 위한 고밀도 지단백 모방 고형 지질 나노입자 및 이의 용도
WO2025043049A2 (en) * 2023-08-22 2025-02-27 Northwestern University Lipoprotein-like nanoparticles with an organic core and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033513A1 (en) * 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
EP2992947A1 (de) * 2014-08-25 2016-03-09 Karlsruher Institut für Technologie Verfahren zur herstellung mikroporöser organischer membranen, mikroporöse organische membranen und deren verwendung
WO2016106328A1 (en) * 2014-12-22 2016-06-30 University Of Georgia Research Foundation, Inc. Nanoparticles for lipid homeostasis

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
CA2679586A1 (en) 2007-02-27 2008-10-23 Northwestern University Molecule attachment to nanoparticles
EP2160464B1 (en) 2007-05-30 2014-05-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP2288336B8 (en) 2008-04-25 2017-03-22 Northwestern University Nanostructures suitable for sequestering cholesterol
WO2011017456A2 (en) 2009-08-04 2011-02-10 Northwestern University Localized delivery of nanoparticles for therapeutic and diagnostic applications
US20120244230A1 (en) 2009-09-01 2012-09-27 Massachusetts Institute Of Technology Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent
US20110111974A1 (en) 2009-10-23 2011-05-12 Northwestern University Short Duplex Probes for Enhanced Target Hybridization
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
WO2011079290A1 (en) 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
AU2011207563B2 (en) 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US20140134658A1 (en) 2010-05-21 2014-05-15 Notrhwestern University, An Illinois Not For Profit Corporation Psa enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness
AU2013222238A1 (en) 2012-02-22 2014-09-18 Northwestern University Nanostructures for treating cancers and other conditions
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
WO2015168393A1 (en) 2014-04-30 2015-11-05 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10517924B2 (en) 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
CA3008837A1 (en) 2015-12-18 2017-06-22 Northwestern University Nitric oxide releasing high density lipoprotein-like nanoparticles (no hdl nps)
SG11201807589RA (en) 2016-03-08 2018-10-30 Univ Northwestern Delivery of nitric oxide-releasing phospholipids, liposomes, and high density lipoprotein-like nanoparticles (hdl nps) by drug eluting stents and intra-arterial injection
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
MX2019002996A (es) 2016-09-15 2019-09-18 Univ Northwestern Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos.
US20210332404A1 (en) 2017-06-21 2021-10-28 Northwestern University Lipid nanoparticles for measuring chronic and acute response to exercise
WO2020219833A1 (en) 2019-04-26 2020-10-29 Northwestern University High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy
EP3965746A4 (en) 2019-05-10 2023-07-19 Northwestern University ORALLY ADMINISTERED LIPID NANOPARTICLES THAT TARGETING AND REVEALING INTESTINAL CD36 AS A MASTER REGULATOR OF SYSTEMIC LIPID HOMEOSTASIS WITH SEX-DIFFERENTIAL RESPONSES
AU2020350707A1 (en) 2019-09-18 2022-03-31 Northwestern University High density lipoprotein-like nanoparticles as inducers of ferroptosis in cancer
US20230173096A1 (en) 2020-05-18 2023-06-08 Northwestern University Targeted antiviral drugs
US12599677B2 (en) 2020-10-05 2026-04-14 Northwestern University Targeted PH sensitive liposomes
CA3199462A1 (en) 2020-10-23 2022-04-28 Northwestern University Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033513A1 (en) * 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
EP2992947A1 (de) * 2014-08-25 2016-03-09 Karlsruher Institut für Technologie Verfahren zur herstellung mikroporöser organischer membranen, mikroporöse organische membranen und deren verwendung
WO2016106328A1 (en) * 2014-12-22 2016-06-30 University Of Georgia Research Foundation, Inc. Nanoparticles for lipid homeostasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRENDA L.SANCHEZ-GAYTAN等: "HDL-Mimetic PLGA Nanoparticle To Target Atherosclerosis Plaque Macrophages", 《BIOCONJUGATE CHEMISTRY》 *
CORBIN，I.R.等: ""Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers"", 《NANOMEDICINE(LOND)》 *
MARRACHE,S.等: "Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis", 《PANS》 *

Also Published As

Publication number Publication date
JP7546927B2 (ja) 2024-09-09
JP2022518479A (ja) 2022-03-15
AU2025260005A1 (en) 2025-11-20
CA3127256A1 (en) 2020-07-30
EP3914236A4 (en) 2022-10-26
US12502354B2 (en) 2025-12-23
US20220151928A1 (en) 2022-05-19
WO2020154705A1 (en) 2020-07-30
AU2020210881A1 (en) 2021-07-22
EP3914236A1 (en) 2021-12-01
SG11202107156WA (en) 2021-08-30
MX2021008940A (es) 2021-11-04

Similar Documents

Publication Publication Date Title
CN113613635A (zh) 使用脂质缀合的核心支架的高密度脂蛋白模拟纳米颗粒
Guo et al. Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2/CCR2 signaling axis and promote drug delivery via SNARE-mediated membrane fusion
Al-Hilal et al. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin
WO2010009065A2 (en) Amphipathic peptide compositions
Hou et al. Co-delivery of siPTPN13 and siNOX4 via (myo) fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy
Chen et al. Morphology-driven protein corona manipulation for preferential delivery of lipid nanodiscs
JP2024526202A (ja) ナノ粒子を含有する核酸
WO2016011049A2 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
CN112274656B (zh) 可将组合药物按比例递送至肿瘤组织的大环两亲自组装纳米颗粒的制备方法和应用
Li et al. Nanostructure of Functional Larotaxel Liposomes Decorated with Guanine‐Rich Quadruplex Nucleotide–Lipid Derivative for Treatment of Resistant Breast Cancer
Zhang et al. Milk exosomes anchored with hydrophilic and zwitterionic motifs enhance mucus permeability for applications in oral gene delivery
Sun et al. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation
Yao et al. Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine
WO2020036987A1 (en) Peptides and compositions for targeted treatment and imaging
Yang et al. Brain-targeted drug delivery by in vivo functionalized liposome with stable D-peptide ligand
Kim et al. Recombinant amphiphilic protein micelles for drug delivery
Zhang et al. The Improved Delivery to Breast Cancer Based on a Novel Nanocarrier Modified with High‐Affinity Peptides Discovered by Phage Display
US10532105B2 (en) Formulations for improving the efficacy of hydrophobic drugs
US11890352B2 (en) Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
KR101229809B1 (ko) 유전자 운반체
JP5914418B2 (ja) 脂質粒子、核酸送達キャリア、核酸送達キャリア製造用組成物、脂質粒子の製造方法及び遺伝子導入方法
US9861707B2 (en) Treating bladder tumor cells using fibronectin attachment protein as a target
Wang et al. Reconstituted high density lipoprotein-based nanoparticles: an overview of applications in regenerative medicine, preparation, evaluation and future trends
Gao et al. The use of a hydrophobic binding peptide modified lipid nanocarrier improving tumor distribution and antitumor efficacy
US20230414509A1 (en) Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211105